Please login to the form below

Not currently logged in


This page shows the latest aducanumab news and features for those working in and with pharma, biotech and healthcare.

Biogen pays $590m for Pfizer cognition drug

Biogen pays $590m for Pfizer cognition drug

Biogen is making a big R&D play in disease associated with cognitive impairment, and PF-04958242 will slot into its pipeline along with Alzheimer’s candidates aducanumab and E2609 in

Latest news

More from news
Approximately 5 fully matching, plus 9 partially matching documents found.

Latest Intelligence

  • The good, the bad and the ugly The good, the bad and the ugly

    Biogen also has Aducanumab in the pipeline, which is forecast to generate huge sales in the future; however, it must be noted that it is being developed for the treatment of

  • Holding on to hope for Alzheimer’s advances Holding on to hope for Alzheimer’s advances

    Data was presented from a Phase Ib study on Biogen’s aducanumab which showed statistically significant reductions in amyloid plaques in the brain compared with placebo among 31 early-stage ... Biogen has begun enrolment in two phase III trials of

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company
Skills in Healthcare

At Skills in Healthcare, we are able to provide our customers with a professional set of sales capabilities. With our...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...